Last reviewed · How we verify
IO102-IO103
IO102-IO103 is a personalized neoantigen vaccine designed to activate the immune system against patient-specific tumor mutations.
IO102-IO103 is a personalized neoantigen vaccine designed to activate the immune system against patient-specific tumor mutations. Used for Melanoma (adjuvant setting), Non-small cell lung cancer (adjuvant setting).
At a glance
| Generic name | IO102-IO103 |
|---|---|
| Sponsor | IO Biotech |
| Drug class | Personalized neoantigen vaccine + checkpoint inhibitor combination |
| Target | Patient-specific neoantigens; CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IO102-IO103 combines IO102 (a personalized neoantigen vaccine) with IO103 (an anti-CTLA-4 checkpoint inhibitor) to enhance anti-tumor immunity. The vaccine targets neoantigens derived from individual patient tumors, while the checkpoint inhibitor removes immune suppression, allowing T cells to mount a more robust response against cancer cells.
Approved indications
- Melanoma (adjuvant setting)
- Non-small cell lung cancer (adjuvant setting)
Common side effects
- Injection site reactions
- Fatigue
- Immune-related adverse events (colitis, hepatitis, pneumonitis)
- Fever
Key clinical trials
- IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer (PHASE1)
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma (PHASE2)
- Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (PHASE2)
- IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) (PHASE3)
- Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma (PHASE1, PHASE2)
- IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC (PHASE2)
- Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |